287 related articles for article (PubMed ID: 24461301)
41. Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis.
Sabbà C; Buonamico P; Vendemiale G; Berardi E; Antonica G; Palmieri V; Merkel C; Palasciano G
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):163-9. PubMed ID: 11246616
[TBL] [Abstract][Full Text] [Related]
42. Influence of carvedilol and propranolol on coronary blood flow.
Sievert H; Frey G; Schräder R; Schmidt T; van der Does R; Kaltenbach M; Kober G
Eur J Clin Pharmacol; 1990; 38 Suppl 2():S122-4. PubMed ID: 1974502
[TBL] [Abstract][Full Text] [Related]
43. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
Rodríguez S; Raurell I; Ezkurdia N; Augustin S; Esteban R; Genescà J; Martell M
Liver Int; 2015 Feb; 35(2):326-34. PubMed ID: 24517276
[TBL] [Abstract][Full Text] [Related]
44. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Bhardwaj A; Kedarisetty CK; Vashishtha C; Bhadoria AS; Jindal A; Kumar G; Choudhary A; Shasthry SM; Maiwall R; Kumar M; Bhatia V; Sarin SK
Gut; 2017 Oct; 66(10):1838-1843. PubMed ID: 27298379
[TBL] [Abstract][Full Text] [Related]
45. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study.
García-Pagán JC; Feu F; Bosch J; Rodés J
Ann Intern Med; 1991 May; 114(10):869-73. PubMed ID: 2014947
[TBL] [Abstract][Full Text] [Related]
46. Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study.
Kim MY; Baik SK; Park DH; Lim DW; Kim JW; Kim HS; Kwon SO; Kim YJ; Chang SJ; Lee SS
Liver Int; 2007 Oct; 27(8):1103-10. PubMed ID: 17845539
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of beta blockers in primary prophylaxis of variceal bleeding in children with portal hypertension.
Samanta T; Purkait R; Sarkar M; Misra A; Ganguly S
Trop Gastroenterol; 2011; 32(4):299-303. PubMed ID: 22696911
[TBL] [Abstract][Full Text] [Related]
48. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis.
Silkauskaitė V; Kupčinskas J; Pranculis A; Jonaitis L; Petrenkienė V; Kupčinskas L
Medicina (Kaunas); 2013; 49(11):467-73. PubMed ID: 24823927
[TBL] [Abstract][Full Text] [Related]
49. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J
Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320
[TBL] [Abstract][Full Text] [Related]
50. Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients.
Eggertsen R; Sivertsson R; Andrén L; Hansson L
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S97-100. PubMed ID: 2454378
[TBL] [Abstract][Full Text] [Related]
51. Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.
Wendt T
Clin Investig; 1992; 70 Suppl 1():S93-7. PubMed ID: 1350491
[TBL] [Abstract][Full Text] [Related]
52. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
McTavish D; Campoli-Richards D; Sorkin EM
Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
[TBL] [Abstract][Full Text] [Related]
53. Beta blockers and cirrhosis, 2016.
Mandorfer M; Reiberger T
Dig Liver Dis; 2017 Jan; 49(1):3-10. PubMed ID: 27717792
[TBL] [Abstract][Full Text] [Related]
54. The Efficacy of Carvedilol in Comparison to Propranolol in Reducing the Hepatic Venous Pressure Gradient and Decreasing the Risk of Variceal Bleeding in Adult Cirrhotic Patients: A Systematic Review.
Dardari L; Taha M; Dahat P; Toriola S; Satnarine T; Zohara Z; Adelekun A; Seffah KD; Salib K; Arcia Franchini AP
Cureus; 2023 Aug; 15(8):e43253. PubMed ID: 37577269
[TBL] [Abstract][Full Text] [Related]
55. Myocardial protection with carvedilol.
Feuerstein GZ; Hamburger SA; Smith EF; Bril A; Ruffolo RR
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S138-41. PubMed ID: 1378142
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
La Mura V; Abraldes JG; Raffa S; Retto O; Berzigotti A; García-Pagán JC; Bosch J
J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
[TBL] [Abstract][Full Text] [Related]
57. Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study.
Schepis F; Vukotic R; Berzigotti A; Carrión JA; Forns X; Abraldes JG; García-Valdecasas JC; Navasa M; García-Pagán JC; Bosch J
Liver Transpl; 2013 Apr; 19(4):450-6. PubMed ID: 23408436
[TBL] [Abstract][Full Text] [Related]
58. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Dunn CJ; Lea AP; Wagstaff AJ
Drugs; 1997 Jul; 54(1):161-85. PubMed ID: 9211087
[TBL] [Abstract][Full Text] [Related]
59. Comparative effectiveness of carvedilol and propranolol on glycemic control and insulin resistance associated with L-thyroxin-induced hyperthyroidism--an experimental study.
Bhatt P; Makwana D; Santani D; Goyal R
Can J Physiol Pharmacol; 2007 May; 85(5):514-20. PubMed ID: 17632586
[TBL] [Abstract][Full Text] [Related]
60. [Pharmacological therapy of portal hypertension--focused on Korean data].
Baik SK
Korean J Gastroenterol; 2005 Jun; 45(6):381-6. PubMed ID: 15973071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
